資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://ir.cmu.edu.tw/ir/handle/310903500/30244
|
| 題名: | Lack of association between pro-inflammatory cytokine (IL-6, IL-8 and TNF-alpha) gene polymorphisms and Graves' disease |
| 作者: | Chen, RH;Chen, WC;Wang, TY;Tsai, CH;Tsai, FJ |
| 貢獻者: | 醫學院醫學系;Taichung Healthcare Management Univ, Taichung, Taiwan;China Med Univ, China Med Univ Hosp, Dept Med, Taichung, Taiwan;China Med Univ, China Med Univ Hosp, Dept Urol, Taichung, Taiwan;China Med Univ, China Med Univ Hosp, Dept Med Genet, Taichung, Taiwan;China Med Univ, China Med Univ Hosp, Dept Pediat, Taichung, Taiwan |
| 日期: | 2005 |
| 上傳時間: | 2010-09-24 14:51:49 (UTC+8) |
| 出版者: | BLACKWELL PUBLISHING |
| 摘要: | Objective: The purpose of this study was to assess the lipid-lowering effect of Monascus purpureus Went rice on serum lipids in patients with hyperlipidemia, and to assess its safety by reporting adverse events and clinical laboratory measurements. Design and methods: This was a randomized. double-blind, placebo-controlled study. In ail, 79 patients (aged 23-65 years) with a mean baseline low-density lipoprotein cholesterol (LDL-C) level of 5.28 mmol/I (203.9 mg/dl) received a twice daily dose of placebo or Monascus purpureus Went rice (600 mg) for 8 weeks. Results: At week 8, Monascus purpureus Went rice therapy reduced LDL-C by 2 7.79%, total cholesterol by 21.5%, triglycerides by 15.8% and apolipoprotein B by 26.0%). High-density lipoprotein cholesterol and apolipoprotein A-I levels were increased by 0.9 and 3.4%, respectively (not significant). No patient in the Monascus purpureus Went rice treatment group had an alanine aminotransferase (ALT), aspartate aminotransferase (AST) or creatine phosphokinase (CPK) measurement that was >= 3 times the upper limit of normal at week 4 and week 8. Conclusion: Monascus purpureus Went rice significantly reduced LDL-C, total cholesterol, triglycerides and apolipoprotein B levels, and was well tolerated in patients with hyperlipidemia. However, this study only provides data from an 8-week trial and long-term safety and efficacy data are needed. |
| 關聯: | INTERNATIONAL JOURNAL OF IMMUNOGENETICS 32(6):343-347 |
| 顯示於類別: | [醫學系] 期刊論文
|
在CMUR中所有的資料項目都受到原著作權保護.
|
